Combination therapy for recurrent ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, open-label, multicohort study aims to evaluate the efficacy and safety of a combination therapy involving AK104, AK112, and chemotherapy in patients with recurrent ovarian cancer. AK104 is a bispecific monoclonal antibody targeting CTLA-4 and PD-1, while AK112 targets VEGF and PD-1. The study will enroll female participants who have histologically diagnosed high-grade epithelial ovarian cancer that has relapsed after standard chemotherapy. Participants will be monitored for treatment response and safety outcomes throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signs the written informed consent form.
2. Female participants who are at least 18 years of age on the day of signing informed consent with.
3. ECOG of 0 or 1.
4. Life expectancy ≥ 3 months.
5. Histologically diagnosed high-grade epithelial ovarian cancer (including high-grade serous, clear cell, G3 endometrioid) that has relapsed after platinum-containing standard chemotherapy.

   1. Recurrence of Platinum-sensitive (relapse ≥6 months after the end of platinum-containing therapy) who is not suitable for platinum-containing therapy after ≥ 3 lines of therapy;
   2. Recurrence of platinum resistance , ≤3 previous lines of therapy. Note: Ovarian cancer includes ovarian cancer, fallopian tube cancer and primary peritoneal cancer in this study, unless otherwise specified.
6. Has measurable disease based on RECIST v1.1 as determined by the site study team.
7. Be able to provide formalin fixed, paraffin-embedded (FFPE) tumor tissue.
8. Has adequate organ function.
9. All subjects of reproductive potential must agree to use an effective method of contraception, during and for 6 months after the last dose of study treatment.

Exclusion Criteria:

1. Other pathological types such as mucinous cancer, low-grade serous carcinoma, carcinosarcoma, sex cord stromal cell tumor, etc.
2. Presence of central nervous system (CNS) metastases or carcinomatous meningitis.
3. Subjects with uncontrollable pleural, pericardial, or peritoneal effusion requiring repeated drainage.
4. Patients with other active malignancies within 3 years prior to randomization.
5. Received systemic anti-tumor therapy within 3 weeks prior to randomization.
6. Any prior treatments targeting the mechanism of tumor immunity.
7. Major surgical treatment, open biopsy or significant trauma within 4 weeks prior to randomization; or elective major surgical treatment required during the study.
8. Active or potentially recurrent autoimmune disease.
9. Subjects who require systemic treatment with glucocorticoid (\> 10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior to randomization.
10. Use of live vaccines within 4 weeks prior to randomization.
11. Known primary or secondary immunodeficiencies, including testing positive for human immunodeficiency virus (HIV) antibodies.
12. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
13. Known history of interstitial lung disease or non-infectious pneumonitis.
14. Serious infections requiring hospitalization.
15. Presence of active infection requiring systemic therapy.
16. Subjects with active hepatitis B and active viral hepatitis C.
17. Active or documented inflammatory bowel diseases, active diverticulitis.
18. Patients with clinically significant cardio-cerebrovascular disease.
19. Unresolved toxicities from prior anticancer therapy.
20. History of severe hypersensitivity reactions to other mAbs.
21. Pregnant or lactating women.
22. Any condition that, in the opinion of the Investigator, may result in a risk when receiving the study drug.
23. Exclusion Criteria for Chemotherapy-Related Cohorts (Cohorts 1,2,4): Known contraindications or allergy to PLD, paclitaxel or topotecan.
24. Exclusion Criteria for AK112-Related Cohorts (Cohorts 2,3,4): Known contraindications or allergy to any component of VEGF mABs or any medical conditions that affect the safety of AK112.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Ting Liu, M.D.
• Email: clinicaltrials@akesobio.com
• Phone: (0760)89873999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SYS6041 in combination therapy for recurrent ovarian cancer

  This study tests SYS6041 combined with other cancer drugs in adults whose ovarian cancer has come back to see if it’s safe and possibly effective.

  Recruiting Phase 2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Shanghai, Shanghai Municipality · NCT07714668

• Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer (REGYNERA-tion) Registry

  This registry tests how reirradiation and total ablative strategies are used in real-world care for adults with recurrent gynecologic cancers and tracks outcomes to see what happens after these treatments.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07667192

• Autologous TILs for Recurrent Ovarian Cancer

  A patient-focused study tests whether a patient’s own tumor-infiltrating lymphocytes can be safely given as a one-time infusion to see if it helps with recurrent ovarian cancer.

  Recruiting CHA University · Gyeonggi-do, Bundang-gu · NCT07651124

• CapsuleX combined with cisplatin for platinum-resistant recurrent ovarian cancer

  This study will try adding CapsuleX to cisplatin to see if it helps people with platinum-resistant recurrent ovarian cancer have better tumor responses.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT07495384

• HS-10502 combination treatment for advanced solid tumors

  This study will test whether the oral drug HS-10502, given with other cancer medicines, is safe and can help people with advanced solid tumors such as recurrent ovarian cancer, HER2‑negative or triple‑negative breast cancer, and advanced prostate cancer.

  Recruiting Phase 1 Jiangsu Hansoh Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06769425

• CPI-0209 combined with Carboplatin for recurrent ovarian cancer

  This study is testing if a new treatment called CPI-0209, when combined with Carboplatin, can help women with recurrent ovarian cancer feel better and stay cancer-free longer.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT05942300

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.